Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IPC-003
- Development stage
- Preclinical
- Lead developer
- Interprotein
- Modality
- Small Molecules
01
Overview
IPC-003 is a small molecule tubulin polymerization inhibitor currently in the preclinical lead generation phase. Developed by Interprotein, the compound is being investigated for the treatment of hematological malignancies, specifically acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Its mechanism of action involves the inhibition of tubulin polymerization, which disrupts microtubule dynamics essential for mitotic spindle formation. This disruption typically leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells, potentially offering a therapeutic approach for leukemias that are resistant to standard treatments.
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on IPC-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IPC-003.